NAIL FUNGUS TREATMENT CLINIC BUSINESS PLAN

I. Executive Summary

Company Description

Name: not provided. Based in Scottsdale, Arizona and launching in 2026, this is a specialized medical clinic in the healthcare sector focused on diagnosing and treating toenail and fingernail fungal infections (onychomycosis). The clinic provides advanced, targeted therapies delivered with state-of-the-art laser technology and a clinical team of licensed podiatry and dermatology specialists. Operating on a fee-for-service model, the practice emphasizes high-quality clinical outcomes and a premium patient experience.

Main activities include clinical diagnosis, laser and adjunctive therapies, treatment planning, and structured follow-up to track outcomes. The clinic differentiates by combining targeted laser treatment, specialist-led care, and a premium service model designed to scale rapidly. Target patients are individuals seeking effective medical resolution for nail fungal infections in Scottsdale and nearby communities. Short-term goal: open and stabilize operations in 2026. Long-term goal: scale services and reach projected revenue of $4,363,000 by year five. Restoring nail health through specialist-led, technology-driven care.

Problem

Persistent toenail and fingernail fungal infections affect millions of Americans and often do not respond to over-the-counter remedies, producing nail discoloration, thickening, brittleness, physical discomfort, and visible stigma; there is a clear need for a professional clinic to treat stubborn nail fungus.

Current care gaps leave patients underserved: primary care and retail treatments often miss diagnosis, under-treat fungal biofilms, and lack follow-up, resulting in chronic symptoms and repeated failed attempts.

The market requires specialized, sustained clinical care delivered by licensed podiatry and dermatology specialists using targeted therapies and state-of-the-art equipment; existing solutions fail to provide diagnosis accuracy, effective biofilm treatment, and structured follow-up.

Solution

Millions of Americans—especially adults age 40+ and those with diabetes—struggle with persistent onychomycosis that resists over-the-counter care. Our clinic launches in 2026 to fill a clear gap by combining licensed podiatry and dermatology expertise with lab-confirmed diagnosis, high-efficacy laser therapy, and physician-managed prescription regimens to deliver measurable nail clearance and restore foot health and confidence.

One-liner: a dedicated clinic offering coordinated, evidence-based care that replaces ineffective OTC approaches and targets full nail restoration, with a first-year revenue target of $681,000.

Mission Statement

Our mission is to restore patients' nail health and confidence by providing the most advanced, specialized nail fungus treatments through cutting-edge technology and a multidisciplinary team. We commit to clinical excellence delivered in a discreet, professional, and empathetic environment and to preventive education that reduces recurrence. We aim to be the definitive solution for chronic nail issues and to set the standard for specialized podiatric and dermatological care in the U.S.

Key Success Factors

Critical factors that will drive clinic utilization, outcomes, and margin.

• Specialized nail-health focus enabling deeper expertise and tailored equipment.
• Physician referral network sustaining projected patient volumes and utilization.
• FDA-cleared laser efficacy delivering the definitive clinical results patients expect.
• Efficient operations driven by EHR systems and a dedicated Clinic Manager for profitability and compliance.
• Targeted marketing reaching high-need 40+ and diabetic patient cohorts.

Financial Summary

The clinic is forecasted to scale from a $681,000 launch-year revenue in 2026 to $2,219,000 in 2028 while reaching breakeven in January 2027.

Financial requirements: minimum cash $597,000 (target month: Dec-26); total payback 27 months; investors should expect an overall IRR of 6.68% and ROE of 6.11%.

Overall outlook: steady growth, improving margins, and positive payback within 27 months.

Funding Requirements

We require USD 597,000 to launch and operate the clinic through the first 12 months; the project targets $681,000 in 2026 revenue and breakeven in January 2027.

Projected performance: revenue grows from $681,000 (2026) to $4,363,000 (2030); EBITDA from $2,000 to $2,693,000; COGS falls to 9% by 2030; total payback 27 months; IRR 6.68%; ROE 6.11%.